Introduction
Transrectal ultrasound guided (TRUS) biopsy is the current verification test for men suspected of having prostate cancer and is estimated to misclassify disease in approximately 30-50% of cases [1] . Men with a negative biopsy or those with low volume prostate cancer seeking accurate risk stratification prior to a treatment decision are often advised or choose to have a further biopsy.
Prostate HistoScanning (PHS) is an ultrasound-based imaging modality, and it works by processing the raw ultrasound signals before they are processed into B mode ultrasound grey scale images. By accessing this information before it has been processed to a grey scale image and processing the ultrasound signals via a number of mathematical algorithms, HistoScanning allows for an output within a selected volume to be determined of cancer vs non-cancer. Early trial of the technology showed promise in detecting and ruling out clinically significant prostate cancer. However, studies assessing its diagnostic performance were often retrospective, not blinded to pathology or based on either TRUS biopsy or whole-mount pathology from radical prostatectomy (RP) [2, 3] . The former is inaccurate and the latter introduces a selection bias as men need to have a positive TRUS biopsy and then choose to have surgery rather than active surveillance or radiotherapy. Thus men undergoing RP are not representative of the population of men in which the imaging modalities may be applied [4] . The Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE trial) [5] was designed to overcome methodological limitations with the literature at the time of conception.
The PICTURE trial was a prospective, paired cohort validating trial, representing level 1b evidence for diagnostic test evaluation [6] . It aimed to assess the diagnostic accuracy of imaging in men who required further biopsies for diagnosis and/or accurate risk stratification of prostate cancer. [5] . Our reference standard was transperineal template prostate mapping (TTPM) biopsies, which are both accurate and avoid many of the biases described. TTPM biopsies can be applied to all men under evaluation, overcome random error of TRUS biopsies by sampling the whole prostate and fix the systematic error by sampling every 5 mm [7, 8] . In this paper, we report on the ability of PHS to detect and rule out clinically significant prostate cancer.
Methods
The PICTURE trial is a single-centre, prospective, ethics committee approved, registered diagnostic paired cohort validating study reported to STARD [9] . The full details of our protocol have been published [10] . Ethics committee approval for the study was granted by London City Road and Hampstead National Research Ethics Committee (reference 11/LO/1657) and the trial was registered with ClinicalTrials.gov (NCT01492270) on 6 December 2011. The study opened to recruitment on 11 January 2012 and completed recruitment on 29 January 2014. We have concurrently submitted the outcomes of another imaging test that was undergoing validation, multiparametric magnetic resonance imaging, as part of a separate manuscript.
Eligibility
Men who had undergone prior TRUS biopsy but where clinical suspicion remained that either prostate cancer had been missed or incorrectly classified were eligible for the study [10] . All men gave informed consent for their inclusion in the trial.
Index test-PHS
All eligible men underwent the PHS carried out with the BK 8818 end-fire probe. PHS was prospectively analysed by experienced reporters using the Prostate-HistoScanning software version 2.1 with a report pro forma designed for the trial. PHS reporting is a semi-automated procedure. The analyst first defines the prostate contours and the software then divides the prostate equidistantly between the base and apical points into base, middle and apex sections, which are further subdivided to left and right. Within the prostate volume, the ultrasound voxels are analysed to deem the likelihood of containing malignant tissue using computerassisted imaging processing algorithms [11, 12] .
Areas deemed suspicious are demonstrated in red overlay to the grey scale ultrasound image. The reporting software used in PICTURE then delineated the three largest PHS suspicious areas (Supplementary Figure 1) . To date, PHS has no way of approximating cancer grade, and therefore significance of lesions at PHS was based on size criteria. Following the work by Wolters et al. within the ERSPC trial, a volume of over 1.3 cc was deemed significant for PHS and further analysis was performed to suspicious volumes over 0.5 cc. [13, 14] Prior to the TPM biopsies, men with PHS lesions had targeted biopsies taken that were visually directed to the largest lesion.
Assessment of variability
Seventy men from the study had repeat PHS scans performed to allow for test-retest reliability. Men also underwent a further scan performed with the BK 8848 side-fire probe; PHS software for this probe was not commercially available.
Reference test
All men then underwent the reference test-transperineal template mapping biopsy (TPM)-which was performed according to a set protocol by trained urologists regardless of the imaging findings and the preceding targeted biopsies. The procedure was carried out under general or spinal anaesthesia with antibiotic prophylaxis and patients in the lithotomy position. A urethral catheter was inserted in order to visualise and avoid traversing the urethral lumen with biopsy needles. Five-mm sampling was obtained using 17 G biopsy core needles inserted via a brachytherapy grid fixed on a stepper. In most prostates, two biopsies at each grid point were required in order to sample the full cranio-caudal length of the gland. At the end of the procedure, the catheter was usually removed unless gross haematuria or swelling was noted that would increase risk of post-procedure retention of urine. All biopsies were reported by expert 2 uro-pathologists of >20 years experience each. All negative biopsies were double-reported for quality control. The histological reporting in our institution follows the classic scheme of interpreting the Gleason grading, the one used before the International Society of Urological Pathology 2005 guidelines [15] . In other words, Gleason scoring was based on the most frequent pattern and not on the highest grade detected on histological analysis. Further, the cancer core length was reported as the actual amount of cancer seen in each core without counting the intervening areas of benign glands [16] .
Target condition
Disease significance was defined on biopsy by criteria that we have previously developed and validated for use with TTPM biopsies [17] . Our primary definition of significance incorporated the presence of Gleason ≥4+3 or more or a maximum cancer core length ≥6 mm in any one location.
Sample size calculation
The sample size calculation was performed for the primary objective of calculating the negative predictive value (NPV) of PHS, using a precision-based estimate [18] [19] [20] . Targeting an NPV of 90% for University College London (UCL) definition 1 disease, for a 95% confidence interval, with a confidence width 10%, the number of patients needed with a negative test was 139. Assuming a prevalence of 38% for UCL definition 1 disease in the population of interest based on prior data at our centre [21] , and assuming the performance characteristics of PHS equate to sensitivity and specificity of approximately 70%, a sample size of 316 patients would allow for 139 patients with a negative test. As the prevalence of men without clinically significant disease was not precisely known in the PICTURE study, an interim analysis at 114 recruited men permitted an adjustment in recruitment to ensure that at least 139 men with a negative reference test were available for analysis.
Statistics
Clinical validity was evaluated on a whole-gland basis using each patient as the unit of assessment. Sensitivity, specificity, positive predictive value (PPV) and NPV were calculated for all eligible men with binomial 95% confidence intervals. Cancer significance at PHS was defined as a suspicious area with volume ≥1.3 ml or secondarily ≥0.5 ml [13, 14] . The histological target condition was defined as UCL definition 1 at the reference test of TTPM biopsy. Overall accuracy was assessed using area under receiver operating characteristic (AUROC) curves. Interobserver variability was assessed using weighted kappa values as well as AUROC curves. STATA version 3.0 software was used with any tests of significance using p = 0.05 as the threshold for statistical significance. Bland Altman was used to compare PHS volumes between the two time points and the two types of probes.
Results

Patient demographics
Three-hundred and thirty men were enrolled. After 110 men were withdrawn (Fig. 1 ), 220 were available for primary analysis. Men eligible for analysis had mean (SD) age 62 years [7] years, median (interquartile range (IQR)) prostate-specific antigen 6.6 (4.98-9.50) ng/ml and median (IQR) number of previous biopsies 1 [1, 2] and mean (SD) gland size 37 ml (15.5) ( Table 1) . Ninety one (41.4%) men had UCL definition 1 significant cancer on biopsy (Table 2) .
Mean (SD) volume for PHS suspicious areas was 3.4 (SD 2.27) ml, with the largest suspicious area in any one prostate measuring mean 2.7 (SD 2.3) ml. PHS tested positive with a suspicious area of ≥1.3 ml.
Primary outcome
In ruling out clinically significant prostate, sensitivity was 70.3% (95% CI 59.8-79.5) with NPV 41.3% (95% CI 27.0-56.8). Specificity and PPV were 14.7% (95% CI 9.1-22.0) and 36.8% (95% CI 29.6-44.4), respectively. Overall accuracy assessed by AUROC curve was 0.43 (0.37-0.48) ( Table 3) .
Secondary outcomes
First, when the target condition was changed to ≥0.5 cc cancer volumes sensitivity and NPV were 93.4% (95% CI 86.2-97.5) and 14.3 (0.4-57.9), respectively. Specificity was 0.8% (95% CI 0.00-4.2) and PPV 39.9 (33.3-46.8), respectively (Table 3 ). Overall accuracy assessed by AUROC curve was 0.47 (0.44-0.50).
Second, 213 of the 220 men had PHS lesions targeted. Sensitivity was 13.6% (95% CI 7.3-22.6), specificity 97.6% (95% CI 93.1-99.5), NPV 61.6% (95% CI 54.5-68.4) and PPV 80.0% (95% CI 51.9-95.7). Of the 213 men targeted based on the PHS, 50 (24%) showed concordance with the TTPM biopsy result. Seventy six (36%) were incorrectly classified as benign or insignificant when they actually harboured clinically significance disease at TTPM biopsy (Table 4) . Three (1.4%) were found to have significant disease at PHS targeted biopsies that were incorrectly classified as insignificant at TTPM biopsy.
Second, when assessing inter-test variability, we scanned 70 men with the 8818 probe at consent and prior to TTPM biopsy. Predicted suspicious area volumes (Supplementary Figure 2) between the two time points showed a mean difference −0.5 cc with lower and upper limits of agreement of −4.99 and 4.89, respectively. The largest suspicious area showed a mean difference 0.07 cc between the two time points with lower and upper limits of agreement of −5.42 to 5.57, respectively (Supplementary Figure 3) . Further, mean gland volumes were 39.43 cc (SD 1.73) and 41.7 cc (SD 1.82) at the first and second time point. Supplementary  Figure 4 shows a Bland Altman plot showing limits of agreement for gland volume with the mean difference between the two time points of 2.3 (lower and upper limits of agreement −9.0 and 13.6, respectively). Third, when assessing inter-probe variability, we scanned 201 men with the 8818 and then the 8848 at baseline. Mean difference between suspicious area volumes was −2.07 cc, with lower and upper limits of agreement of −8.90 and 4.76, respectively. The main area of suspicious had mean differences between the two probes of 2.18c c, with lower and upper limits of agreement of −9.40 to 5.04, respectively (Supplementary Figure 5) .
Fourth, there were no serious adverse events resulting from PHS. Serious adverse events resulting from TTPM biopsy occurred in 9 (3.6%) men. Adverse events were captured in 236 patients in a median of 38 ± 56 days after biopsy. Haematuria and poor urine flow were reported, respectively, in 220 (93.2%) and 108 (45.8%). Urinary retention was diagnosed in 56 (23.7%). Urinary tract infection was diagnosed in 23 (9.8%) and perineal skin infection in 8 (3.4%). Rectal and perineal pain and perineal bruising were reported in 59 (25.1%), 95 (40.3%), and 136 (57.6%), respectively. De novo erectile dysfunction occurred in 20.8%. Most were temporary with two requiring oral medication.
Discussion
In summary, our PICTURE trial shows that PHS has poor accuracy in men requiring further biopsies. Further, it also has poor performance when using it as a targeting modality. We also demonstrated poor reliability of gland and lesion volume both between time points with the same probe and between the two types of probes when performing PHS.
There are some limitations to our study. First, due to technical failures with the PHS device and consequent loss of data for reporting, several men were withdrawn after consent. Second, we relied heavily on the automated reporting software with minimal manual refinement. At the time, the device manufacturers advised a manual 'refinement' to the predicted suspicious areas to remove areas thought to contain poor ultrasound data. This was a highly subjective measure that we felt was not easily reproducible and standardised by all users of the technology. Third, our targeting technique was one based on visual estimation as an image-fusion platform for real-time PHS to live ultrasound was not available. Real-time targeting might have enhanced the localisation of the target and reduced targeting errors. Fourth, PHS as an ultrasound modality is known to be user dependent. Although all scans in our study were acquired by trained clinicians signed off for competency in the technique, there may be some element of variability.
Also owing to no grade estimation for PHS being available, significance criteria were size based (≥1.3 ml), this cutoff was larger in volume than the size criteria for TTPM and this cutoff was chosen as preliminary work had demonstrated some size discrepancy between PHS and final pathology sizing. Our secondary analysis examined 0.5 ml PHS lesions vs 0.5 ml TTPM lesions. Finally, the exclusion of larger glands for safety reasons could have added an element of selection bias to the study that may have had a degree of impact on our results.
There has been a degree of controversy surrounding PHS in the literature [22] , with initial proof-of-concept study results for the technology demonstrating very high performance characteristics with sensitivity and specificity of 100% and 82% for the detection of 0.5 cc lesions, respectively [11, 12] . Further studies showed sensitivities ranging from 37% to 90% and specificity 33-71% [23] [24] [25] . Most of these were small single-centre studies. The largest study of PHS to date was a retrospective series by Schiffman et al. [26] looking at the volume of cancer at PHS and RP, which showed very little correlation of the size of PHS and RP lesions. The same group assessed the ability of PHS to predict positive biopsy [27] and found, as we did in the PICTURE study, that PHS has a rate of false positives, which artificially inflated sensitivity.
To date, PICTURE is the largest prospective study of PHS in a cohort of men requiring further biopsies, against an accurate reference test, TTPM biopsy, which was able to minimise biases. Most other cohorts have been small, retrospective, not blinded and used either TRUS biopsy or whole-mount histology with the inaccuracy and biases these introduce.
PHS, although demonstrating reasonable sensitivity (70%) in this cohort of men, showed poor specificity, PPV and NPV. For a test to be useful in the prostate cancer pathway, it needs to not only accurately detect clinically significant cancer but also rule out clinically significant cancer. The specificity and NPV in this cohort were poor at 14.7% and 41.3%, respectively. The overall accuracy seemed at best to be no better than chance.
The PHS reliability work in PICTURE showed that the outputs of PHS, both in terms of gland size and lesion volume, were not stable between two time points using the same probe. Agreement between scans at different time points was seen to be poor with a mean difference of 2.3 cc but limits of agreement for gland size varying wildly from −9 to 13.6. The high variability in both the volume of the prostate gland and the volume of prostate lesions seen using PHS in this cohort deem the test unreliable as well as inaccurate.
Conclusion
The PHS results from the PICTURE study have shown that this imaging test has a poor ability to discriminate benign from malignant tissue. PHS has also not shown any promise in the guidance of prostate biopsy. These poor performance characteristics mean that it has no place in the prostate cancer diagnostic pathway.
